Pharmacy Operations Can Enhance Reimbursement Picture for Oncology Drugs
Pharmacists can play a role in the drug reimbursement process for oncology products, which are among the most expensive of all pharmaceuticals.
Related Articles
Dr Lorusso on the Use of Selective Glucocorticoid Receptor Modulators in Recurrent Ovarian Cancer
Domenica Lorusso, MD, PhD, discusses the rationale for investigating relacorilant combined with nab-paclitaxel in recurrent, platinum-resistant ovarian cancer.
Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCC
James J. Harding, MD, discusses how immunotherapy could play a role in earlier stages in hepatocellular carcinoma.
Afami-Cel Shows Durable Persistence and Tumor-Killing Abilities in Synovial Sarcoma
Treatment with afami-cel was associated with long-term persistence in the periphery that led to clinical benefit in patients with synovial sarcoma.
Retrospective Data Show Pacritinib Improves TSS in Transfusion-Dependent Myelofibrosis
A retrospective study showed pacritinib improved symptoms in transfusion-dependent myelofibrosis.
Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers for 2024
Dana-Farber Cancer Institute announced that 42 of its researchers have been named to the Highly Cited Researchers list of 2024.
EMA Grants PRIME Designation to NX-5948 for R/R CLL/SLL
NX-5948 has received PRIME designation from the EMA for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.
An Era of Firsts in CML: Asciminib Challenges SOC TKIs
Jorge E. Cortes, MD, details how asciminib is improving upon first- and second-generation SOC TKIs in chronic myeloid leukemia.
PYX-201 Generates Responses in Pretreated Advanced HNSCC and Other Solid Tumors
PYX-201 produced responses in heavily pretreated head and neck squamous cell carcinoma and other solid tumors.
Kidney Cancer NCCN Guidelines Receive Major Updates, Prostate Cancer Adds Targeted Agents
Sandy Srinivas, MD, details updates from 2024 in the kidney and prostate cancer NCCN guidelines and agents/trials to look forward to in 2025.
Real-World Experience With CAR T Varies From Trials in DLBCL
When evaluating real-world experience, differences in race/ethnicity and among elderly patients with DLBCL appeared different from those seen in clinical trials, highlighting the need for…